POLIPLI RINOSINUSITDA 2-TIP YALLIG'LANISHNING O'RNI

Authors

  • Mamataliyev Barhayot Abdullayevich Otorinolaringologiya yo‘nalishi 1-bosqich ordinatori Central Asian Medical University

Keywords:

poliplı rinosinusit, 2-tip yallig'lanish, IL-4, IL-5, IL-13, eozinofiliya, ILC2, dupilumab, nazal poliplar, endotip

Abstract

 

 Poliplı rinosinusit (PRS) burun bo'shlig'i va paranazal bo'shliqlar shilliq qavatining surunkali yallig'lanish kasalligi bo'lib, populyatsiyaning taxminan 2–4% ida uchraydi. So'nggi yillarda o'tkazilgan immunologik tadqiqotlar PRSning ko'pchilik holatlarida patogenezning markazida 2-tip yallig'lanish (Type 2 inflammation) yotishini ko'rsatdi. Ushbu jarayon Th2-limfotsitlar va 2-tip tug'ma limfoid hujayralar (ILC2) tomonidan ishlab chiqariladigan IL-4, IL-5 va IL-13 sitokinlari, shuningdek eozinofillar, tuchan hujayralar va IgE bilan bog'liq mexanizmlar orqali amalga oshadi. Maqolada 2-tip yallig'lanishning molekulyar mexanizmlari, uning nazal poliplar shakllanishidagi roli, klinik ko'rinishlarga ta'siri (astma va aspirin intoleransligi bilan uyg'unlashuvi — AERD/Samter triadasi), hamda biologik terapiya (dupilumab, mepolizumab, omalizumab) samaradorligi tahlil qilingan. Xulosa qilib aytganda, 2-tip yallig'lanish endotipini aniqlash zamonaviy shaxsiylashtirilgan davolash strategiyasini tanlashda muhim ahamiyat kasb etadi.

References

Bachert C. et al. Effect of dupilumab on type 2 biomarkers in chronic rhinosinusitis with nasal polyps: SINUS-52 study results.

Bachert C., Han J.K., Desrosiers M. et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps. Lancet.

Current understanding of epithelial-derived alarmins in chronic rhinosinusitis with nasal polyps. 2025.

Fokkens W.J., Lund V.J., Hopkins C. et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl S29):1–464.

Gevaert P., Calus L., Van Zele T. et al. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol.

Gevaert P., Omachi T.A., Corren J. et al. Omalizumab in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol.

Han J.K., Bachert C., Fokkens W. et al. Mepolizumab for chronic rhinosinusitis with nasal polyps. N Engl J Med.

Identification of inflammatory endotypes by clinical characteristics and nasal secretion biomarkers in chronic rhinosinusitis with nasal polyps.

Kato A. Immunopathology of chronic rhinosinusitis. Allergology International. 2015.

Mullol J. et al. Olfactory outcomes with dupilumab in chronic rhinosinusitis with nasal polyps.

Schleimer R.P. Immunopathogenesis of chronic rhinosinusitis and nasal polyposis. Annu Rev Pathol.

Stevens W.W., Schleimer R.P., Kern R.C. Chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2016;4(4):565–572.

The advance on pathophysiological mechanisms of type 2 chronic rhinosinusitis with nasal polyposis. 2025.

The use of biological therapies in the treatment of chronic rhinosinusitis with nasal polyps: current state of knowledge. 2026.

Tomassen P. et al. Sinonasal biomarkers defining type 2-high and type 2-low inflammation in chronic rhinosinusitis with nasal polyps.

Downloads

Published

2026-09-28